Study guide

18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

NBCRNA CRNA Certified Registered Nurse Anesthetist NCE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology

1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems

2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives

3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics

5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies

5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout

6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators

6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging

7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation

7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways

8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety

8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety

9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation

9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication

10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies

11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms

11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)

12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA

12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm

13 Chapter 13: Regional Anesthesia: Neuraxial Blocks

13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma

14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance

14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols

15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice

15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives

16 Chapter 16: Obstetric & Gynecologic Anesthesia

16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient

17 Chapter 17: Pediatric Anesthesia

17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm

18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia

18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction

20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia

20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation

21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology

21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements

22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology

22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices

23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures

23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases

24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control

24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure

25 Chapter 25: Neurosurgical Subspecialty Procedures

25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy

26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia

26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery

27 Chapter 27: Orthopedic & Extremity Anesthesia

27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block

28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy

28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia

29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients

29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient

18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

Key Takeaways Explain This Topic AI

Patient selection for ambulatory surgery focuses on medical optimization rather than strict ASA physical status; stable ASA I, II, and optimized ASA III patients are appropriate candidates, whereas unoptimized cardiopulmonary disease, active substance withdrawal, and ex-premature infants with a post-conceptual age < 60 weeks (due to high apnea risk) require inpatient admission.

Malignant Hyperthermia (MH) susceptible patients may safely undergo elective outpatient surgery utilizing a total trigger-free anesthetic technique (TIVA, avoiding succinylcholine and all volatile agents) and a dedicated machine clean-up protocol, provided the center stocks adequate dantrolene/ryanodex and observes the patient for at least 60-90 minutes postoperatively.

Enhanced Recovery After Surgery (ERAS) pathways integrate multimodal preoperative interventions (carbohydrate loading up to 2 hours preoperatively, minimal fasting, pre-emptive non-opioid analgesics), intraoperative bundles (opioid-sparing TIVA, lidocaine/ketamine infusions, regional nerve blocks, goal-directed fluid therapy, active normothermia), and postoperative pathways (early oral nutrition and rapid ambulation).

Goal-Directed Fluid Therapy (GDFT) utilizes dynamic indices of preload responsiveness (Stroke Volume Variation [SVV] > 12-13% or Pulse Pressure Variation [PPV] > 13% during positive-pressure mechanical ventilation) to guide fluid administration, avoiding both hypervolemic glycocalyx shedding and hypoperfusion-induced organ ischemia.

Fast-tracking allows eligible ambulatory surgical patients to bypass Phase I PACU directly to Phase II step-down recovery if they achieve a White-Song Fast-Track Score ≥ 12 (with no single score < 1), significantly decreasing facility costs and recovery times without compromising clinical safety.

Last updated: August 2026

18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

Ambulatory surgery accounts for over 70 % 70\% 70% of all elective surgical procedures performed in North America. Successful outpatient anesthesia requires stringent patient and procedure selection, proactive risk management, and the implementation of Enhanced Recovery After Surgery (ERAS) protocols designed to minimize postoperative pain, nausea, and convalescence time.

1. Ambulatory Patient & Procedure Selection Guidelines

Appropriateness for the ambulatory surgery center (ASC) setting is dictated by the interaction between the patient's medical status, the invasiveness of the surgical procedure, and social support systems. +---------------------------------------------------------------------------------------------------------+

  • | AMBULATORY SURGERY SELECTION FRAMEWORK |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | Domain | Appropriate for Ambulatory Center | Excluded / Requires Hospital Admission |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **ASA Status** | • ASA Class I & II | • Unstable ASA Class III or Class IV |
  • | | • **Optimized, stable ASA Class III**| • Acute organ failure or decompensation |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Cardiopulmonary** | • Controlled hypertension, mild CAD | • Unstable angina, recent MI (<60 days) |
  • | | • Well-controlled asthma / COPD | • Symptomatic severe aortic stenosis |
  • | | • Compliant OSA with CPAP access | • Severe pulmonary hypertension, decomp HF|
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Pediatric Age** | • Full-term infants > 44 weeks PCA | • **Ex-premature infants < 60 weeks PCA**|
  • | | • Children without active apnea | (mandatory overnight apnea monitoring) |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Substance & Social**| • Responsible adult escort available | • Acute intoxication / active withdrawal |
  • | | • Patient capable of home self-care | • No responsible adult caregiver at home |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Surgical Factors** | • Minimal anticipated blood loss | • Major cavity exploration, open thorax |
  • | | • Duration typically < 3 - 4 hours | • High risk for major fluid shifts/hemorr|
  • | | • Postop pain manageable with oral Rx| • Mandatory prolonged immobilizing care |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • The Ex-Premature Infant: Post-Conceptual Age (PCA) Rule

Post-Conceptual Age Calculation: PCA (weeks) = Gestational Age at Birth (weeks) + Chronological Age (weeks) \text{PCA (weeks)} = \text{Gestational Age at Birth (weeks)} + \text{Chronological Age (weeks)} PCA (weeks) = Gestational Age at Birth (weeks) + Chronological Age (weeks)

Apnea Risk: Former premature infants ( < 37 weeks <37 \text{ weeks} < 37 weeks gestation) have immature central respiratory centers and are at high risk for life-threatening postoperative apnea, bradycardia, and hypoxemia for up to 12 − 24 hours 12 - 24 \text{ hours} 12 − 24 hours following general anesthesia.

The 60-Week Cutoff Standard: Any ex-premature infant whose PCA < 60 weeks \text{PCA} < 60 \text{ weeks} PCA < 60 weeks must NOT undergo elective outpatient surgery in a freestanding ASC. They require surgery in a hospital setting followed by continuous inpatient cardiorespiratory (apnea) monitoring for at least 12 − 24 hours 12 - 24 \text{ hours} 12 − 24 hours postoperatively.

Malignant Hyperthermia (MH) Susceptibility in the ASC

Patients with known or suspected MH susceptibility CAN safely undergo elective procedures in an ambulatory surgery center provided specific safety criteria are satisfied:

Total Trigger-Free Anesthesia: Absolute avoidance of all volatile inhalational agents (sevoflurane, desflurane, isoflurane) and succinylcholine. Use Propofol TIVA, local/regional anesthesia, or nitrous oxide.

Anesthesia Machine Preparation: Vaporizers removed or physically locked; machine flushed with high-flow 100 % O 2 100\% \text{ O}_2 100% O 2 ​ ( 10 L/min 10 \text{ L/min} 10 L/min for 20 − 90 minutes 20 - 90 \text{ minutes} 20 − 90 minutes according to manufacturer guidelines) or activated charcoal filters (Vapor-Clean) placed on inspiratory and expiratory limbs.

Stocked Reversal Agent: The facility must have a complete MH emergency cart containing Dantrolene (36 vials of 20 mg 20 \text{ mg} 20 mg ) or Ryanodex (3 vials of 250 mg 250 \text{ mg} 250 mg ) with sterile water for reconstitution.

Postoperative Observation: Observe in Phase I/II PACU for at least 60 − 90 minutes 60 - 90 \text{ minutes} 60 − 90 minutes ; if uneventful, the patient may be safely discharged home.

2. Enhanced Recovery After Surgery (ERAS) Care Pathways

ERAS represents a multidisciplinary, evidence-based paradigm that attenuates the surgical stress response, maintains physiological homeostasis, reduces organ dysfunction, and accelerates post-surgical recovery. +---------------------------------------------------------------------------------------------------------+

  • | ERAS PERIOPERATIVE CARE CONTINUUM |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | Perioperative Phase | Core Evidence-Based Interventions | Physiologic Rationale & Outcome |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Preoperative** | • Fasting: Clear liquids up to 2h | • Attenuates catabolism, dehydration, |
  • | | • **Carbohydrate Loading (maltodex)**| and postop insulin resistance |
  • | | • Pre-emptive multimodal non-opioid | • Acetaminophen + Celecoxib + Gabapentin |
  • | | analgesia (oral) | attenuates central/peripheral sensitiz |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Intraoperative** | • **Opioid-Sparing Multimodal TIVA** | • Propofol TIVA + Lidocaine/Ketamine inf |
  • | | • Regional / Fascial Plane Blocks | • TAP, ESP, Rectus sheath, Adductor canal|
  • | | • **Goal-Directed Fluid Rx (GDFT)** | • Protects endothelial glycocalyx |
  • | | • Prophylactic Antiemetic Dual/Triple| • Dexamethasone + Ondansetron + Scopolam |
  • | | • **Active Normothermia (>36.0°C)** | • Warming blankets reduce SSI & bleeding |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Postoperative** | • **Early Oral Nutrition** (liquids) | • Accelerates return of bowel motility |
  • | | • **Early Ambulation** within hours | • Prevents VTE, atelectasis, ileus |
  • | | • Prompt urinary catheter removal | • Reduces CAUTI, promotes mobilization |
  • | | • Transition to oral non-opioid meds | • Minimizes opioid-induced bowel dysfunct|

+-----------------------+--------------------------------------+------------------------------------------+ [THE MULTIMODAL OPIOID-SPARING BUNDLE]

  • [SURGICAL TRAUMA]
  • |
  • +--------------------+---------+---------+--------------------+
  • | | | |
  • v v v v
  • [COX-2 Inhibitor] [Acetaminophen] [IV Lidocaine] [Ketamine]
  • (Celecoxib) (Central COX) (Sodium Channel (NMDA Receptor
  • Peripheral Prosta- Antipyretic / & Anti-Inflammatory) Antagonist)
  • glandin Blockade Analgesic Suppresses Ectopic Prevents Central
  • Neural Firing Wind-Up / Hyperalg
  • | | | |
  • +--------------------+---------+---------+--------------------+
  • |
  • v
  • **OPIOID CONSUMPTION ↓ 50-70%**
  • **PONV ↓, ILEUS ↓, SEDATION ↓**
  • Intraoperative Non-Opioid Adjuvants

Intravenous Lidocaine Infusion:

Loading Dose: 1.0 − 1.5 mg/kg 1.0 - 1.5 \text{ mg/kg} 1.0 − 1.5 mg/kg IV bolus at induction.

Continuous Infusion: 1.5 − 2.0 mg/kg/h 1.5 - 2.0 \text{ mg/kg/h} 1.5 − 2.0 mg/kg/h throughout surgery.

Benefits: Sodium channel blockade suppresses spontaneous pain transmission, attenuates visceral peritoneal pain, accelerates bowel motility recovery, and exerts systemic anti-inflammatory effects.

Subanesthetic Ketamine Infusion:

Loading Dose: 0.2 − 0.5 mg/kg 0.2 - 0.5 \text{ mg/kg} 0.2 − 0.5 mg/kg IV bolus.

Continuous Infusion: 0.1 − 0.25 mg/kg/h 0.1 - 0.25 \text{ mg/kg/h} 0.1 − 0.25 mg/kg/h ( 2 − 4 mcg/kg/min 2 - 4 \text{ mcg/kg/min} 2 − 4 mcg/kg/min ).

Benefits: Non-competitive antagonism of N N N -methyl- D D D -aspartate (NMDA) receptors prevents spinal dorsal horn neuronal "wind-up," prevents acute opioid-induced hyperalgesia (OIH), and significantly reduces postoperative morphine consumption.

Dexmedetomidine (Precedex):

Selective α 2 \alpha_2 α 2 ​ -agonist ( 0.2 − 0.5 mcg/kg/h 0.2 - 0.5 \text{ mcg/kg/h} 0.2 − 0.5 mcg/kg/h ) providing sedation, anxiolysis, and analgesia without respiratory depression.

Goal-Directed Fluid Therapy (GDFT) & Glycocalyx Integrity

Static vs. Dynamic Measures: Static parameters (Central Venous Pressure [CVP], blood pressure, heart rate) correlate poorly with fluid responsiveness. GDFT relies on dynamic cardiopulmonary interactions during positive-pressure mechanical ventilation:

Stroke Volume Variation ( S V V SVV S VV ): Normal ≤ 10 − 12 % \le 10 - 12\% ≤ 10 − 12% . S V V > 12 − 13 % SVV > 12 - 13\% S VV > 12 − 13% indicates fluid responsiveness.

Pulse Pressure Variation ( P P V PPV PP V ): P P V > 13 % PPV > 13\% PP V > 13% indicates fluid responsiveness (requires tidal volume ≥ 8 mL/kg \ge 8 \text{ mL/kg} ≥ 8 mL/kg , sinus rhythm, and closed chest).

Protecting the Endothelial Glycocalyx: Hypervolemia causes secretion of Atrial Natriuretic Peptide (ANP), which degrades the fragile endothelial glycocalyx barrier, promoting interstitial fluid extravasation, tissue edema, pulmonary compromise, and prolonged postoperative ileus. GDFT targets euvolemia with balanced crystalloids ( 1 − 3 mL/kg/h 1 - 3 \text{ mL/kg/h} 1 − 3 mL/kg/h maintenance plus targeted boluses).

3. Fast-Tracking & Post-Anesthesia Recovery Scoring

Fast-tracking refers to the clinical pathway wherein patients emerging from general, regional, or MAC anesthesia bypass the Phase I PACU and are transferred directly from the operating room to the Step-Down Phase II unit. +---------------------------------------------------------------------------------------------------------+

  • | WHITE-SONG FAST-TRACK SCORING SYSTEM |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | Assessment Category | Clinical Evaluation Criteria | Score |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **1. Physical Activity**| • Moves all 4 extremities voluntarily or on command | 2 |
  • | | • Moves 2 extremities voluntarily | 1 |
  • | | • Unable to move extremities | 0 |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **2. Hemodynamics** | • Blood pressure within ± 15% of preop baseline | 2 |
  • | | • Blood pressure within ± 15% to 30% of baseline | 1 |
  • | | • Blood pressure within ± >30% of baseline | 0 |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **3. Respiratory** | • Breathes easily, normal rate and depth, coughs freely | 2 |
  • | | • Dyspneic, shallow breathing, requires oral/nasal airway | 1 |
  • | | • Apneic / requires mechanical ventilation | 0 |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **4. Consciousness** | • Fully awake, alert, and oriented to person, place, time | 2 |
  • | | • Arousable by verbal stimuli | 1 |
  • | | • Unresponsive / responds only to painful stimuli | 0 |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **5. Oxygen Saturation**| • SpO₂ > 92% on room air | 2 |
  • | | • Requires supplemental O₂ to maintain SpO₂ > 90% | 1 |
  • | | • SpO₂ < 90% despite supplemental O₂ | 0 |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **6. Postoperative Pain**| • None or mild discomfort (Visual Analog Scale 0 - 2) | 2 |
  • | | • Moderate pain controllable with non-opioids (VAS 3 - 5) | 1 |
  • | | • Severe persistent pain requiring IV opioids (VAS > 5) | 0 |
  • +-------------------------+---------------------------------------------------------------------+---------+
  • | **7. Emetic Symptoms** | • No nausea or vomiting | 2 |
  • | | • Transient mild nausea successfully treated with oral fluids/meds | 1 |
  • | | • Persistent nausea or vomiting requiring parenteral antiemetics | 0 |

+-------------------------+---------------------------------------------------------------------+---------+ Fast-Track Transfer Criteria: Total Score ≥ 12 / 14 ( with NO individual score < 1 ) \mathbf{\text{Fast-Track Transfer Criteria: Total Score } \ge 12 / 14 \quad (\text{with NO individual score } < 1)} Fast-Track Transfer Criteria: Total Score ≥ 12/14 ( with NO individual score < 1 )

Ambulatory Discharge to Home: Post-Anesthesia Discharge Scoring System (PADSS)

Prior to home discharge from Phase II, the patient must achieve a PADSS ≥ 9 / 10 \text{PADSS} \ge 9 / 10 PADSS ≥ 9/10 across 5 categories: vital signs, ambulation, nausea/vomiting, pain, and surgical bleeding.

Modern Standard: Routine mandatory voiding and mandatory oral liquid intake are no longer required for all patients prior to discharge unless specifically indicated (e.g., neuraxial anesthesia, pelvic/groin surgery, history of urinary retention).

Loading diagram... Comprehensive ERAS & Ambulatory Fast-Tracking Clinical Pathway